Online inquiry

IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5252MR)

This product GTTS-WQ5252MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5252MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3296MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ3425MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AV-299
GTTS-WQ3210MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARGX-110
GTTS-WQ4675MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986089
GTTS-WQ11175MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI0562
GTTS-WQ11111MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ13327MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ16008MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ZW-25
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW